Register Now

Accreditation & Disclosures

Accredited by

In support of improving patient care, this activity has been planned and implemented by The Medical Educator Consortium and IDEOlogy Health. The Medical Educator Consortium is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 9.50 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physician

The Medical Educator Consortium designates this live activity for a maximum of 9.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing

The Medical Educator Consortium designates this activity for 9.5 contact hours.

Pharmacist

This Application-based activity has been approved for 9.5 contact hours (.095 CEU) by The Medical Educator Consortium. The Universal Activity Number for this program is JA4008179-9999-23-005-L01-P. Your CE credits will be electronically submitted to CPE Monitor® within 60 days upon successful completion of the activity.

Physician Associate

AAPA

The Medical Educator Consortium has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 9.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Disclosure Policy

The Medical Educator Consortium (MEC) adheres to the Joint Accreditation Criteria and the ACCME Standards for Integrity and Independence in Accredited Continuing Education. As a Joint Accreditation (JA) provider, decisions in the planning process of this conference were made free of the control of ineligible companies. All persons that will be in a position to control the content of the CE Activity are required to disclose all relevant financial relationships, regardless of the amount, that they have had in the past 24 months with ineligible companies. MEC has implemented a mechanism to identify, mitigate and disclose relevant financial relationships prior to the education activity being delivered to learners. A Disclosure Index document outlining this information will be made available to participants prior to the educational activity. The source of all commercial support from ineligible companies will also be disclosed to learners prior to the beginning of the educational activity. CE activities must be balanced, independent of commercial bias, and designed to improve quality in health care. All recommendations involving clinical medicine must be based on evidence within the medical profession.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contradictions, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contradictions and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

To view the DISCLOSURE INDEX please open the following PDF:

The Medical Educator Consortium, Inc. in accordance with the Joint Accreditation Criteria and the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, has implemented a process where everyone who is in a position to control the content of a CME/CE activity has disclosed to us all relevant financial relationships with any ineligible company that they have had over the past 24 months. There is no minimum financial threshold; disclosure must be made regardless of whether the person views the financial relationships as relevant to the education. The ACCME defines an ineligible company as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. MEC has implemented a mechanism to identify, mitigate and disclose relevant financial relationships prior to the education activity being delivered to learners.


As a Joint Accreditation (JA) Provider, decisions in the planning process of this conference were made free of the control of ineligible companies. All individuals who are in a position to control the content of this educational activity have disclosed all relevant financial relationships with any ineligible companies to the provider. This disclosure includes all persons in control of content to include staff and educational committee members involved in the planning process.

The ACCME defines an ineligible company as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies.

Speakers/Moderators – Reported Relevant Financial Disclosure(s)

Alexander Anderson, PhD
Has no relevant financial relationships Sheena Bhalla, MD Advisory Board: Takeda

Hossein Borghaei, DO, MS
Grant/Research Support: BMS, Lilly, Amgen Consultant: BMS, Lilly, Genentech, Pfizer, Merck, EMD Serono, Boehringer Ingelheim, AstraZeneca, Novartis, Genmab, Regeneron, BioNTech, Amgen, Axiom, PharmaMar, Takeda, Mirati Therapeutics, Daiichi, Guardant, Natera, Oncocyte, BeiGene, iTEO, Jazz Pharmaceuticals, Janssen, Da Volterra Speakers’ Bureau: Amgen, Pfizer, Daiichi Sankyo, Regeneron, BMS, Merck, Lilly, EMD Serono, Genentech Stock Shareholders: Sonnet BioTherapeutics, Inspirna, Nucleai Other: Data Safety Monitoring Board: Takeda, Incyte, Novartis

Lauren Byers, MD
Grant/Research Support: AstraZeneca Pharmaceuticals Consultant: Merck, Sharp & Dohme Corp., Arrowhead Pharmaceuticals, Chugai Pharmaceutical Co., AstraZeneca, Genentech Inc., BeiGene, AbbVie

Tina Cascone, MD, PhD
Grant/Research Support: MedImmune/AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, EMD Serono Consultant: MedImmune/AstraZeneca, Bristol Myers Squibb, Merck, Genentech, Arrowhead Pharmaceuticals, Regeneron Speakers’ Bureau: Roche, Bristol Myers Squibb, Dava Oncology

Ibiayi Dagogo-Jack, MD
Grant/Research Support: Array BioPharma, Genentech, Novartis, Pfizer, Guardant Health Consultant: Foundation Medicine, DAVA Oncology, Triptych Health Partners, Aptitude Health, AstraZeneca, Boehringer Ingelheim, Bayer, BostonGene, Bristol Myers Squibb, Catalyst, Genentech, Janssen, Novocure, Pfizer, Sanofi-Genzyme, Syros, and Xcovery

Jessica Donington, MD, MSCR
Consultant: AstraZeneca, BMS, Roche/Genentech Speakers' Bureau: AstraZeneca, Roche/Genentech

Yasir Elamin, MD
Grant/Research Support: AstraZeneca, Takeda, Eli Lilly, Xcovery, Tuning Point Therapeutics, Blueprint, Elevation Oncology, Spectrum Pharmaceuticals, Nuvalent Consultant: AstraZeneca, Eli Lilly, Takeda, Spectrum Pharmaceuticals, Bristol Myers Squibb, and Turning Point Therapeutics Speakers’ Bureau: Eli Lilly

Narjust Florez (Duma), MD
Advisory/Consultant: Merck, Pfizer, BMS, Janssen, AstraZeneca, DSI, Novartis, NeoGenomics

Shirish Gadgeel, MD
Consultant: Genentech/Roche, AstraZeneca, Takeda, BMS, Pfizer, Mirati Therapeutics, Daichii Sankyo, Janssen, Eisai, Merck, Lilly, Blueprint, Glaxo Smith Kline Speakers’ Bureau: Mirati Therapeutics Other: IDMC AstraZeneca

Balazs Halmos, MD
Grant/Research Support: Boehringer Ingelheim, AstraZeneca, Merck, BMS, Advaxis, Amgen, AbbVie, Daiichi Sankyo, Pfizer, GSK, BeiGene, Janssen Consultant: AstraZeneca, Boehringer Ingelheim, Apollomics, Janssen, Takeda, Merck, BMS, Genentech, Pfizer, Eli Lilly, TPT, Arcus Biosciences, Veracyte

John Heymach, MD, PhD
Grant/Research Support: AstraZeneca, Bristol Myers Squibb, Spectrum, Takeda Advisory Committees – AstraZeneca, EMD Serono, Boehringer-Ingelheim, Catalyst, Genentech, GlaxoSmithKline, Hengrui Therapeutics, Eli Lilly, Spectrum Pharmaceuticals, Sanofi, Takeda, Mirati Therapeutics, BMS, BrightPath Biotherapeutics, Janssen Global Services, Nexus Health Systems, Pneuma Respiratory, Kairos Venture Investments, Roche, Leads Biolabs, RefleXion, Chugai Pharmaceuticals Stock Shareholders: Spectrum Pharmaceuticals Other: Royalties and Licensing fees – Spectrum Pharmaceuticals

Kristin Higgins, MD
Grant/Research Support: Jazz Pharmaceuticals, RefleXion Medical Consultant: AstraZeneca, Janssen Pharmaceuticals, Genentech

Melissa Johnson, MD
Grant/Research Support: AbbVie, Acerta, Adaptimmune, Amgen, Apexigen, Arcus Biosciences, Array BioPharma. Artios Pharma, AstraZeneca, Atreca, BeiGene, BerGenBio, BioAtla, Black Diamond, Boehringer Ingelheim, Calithera Biosciences, Carisma Therapeutics, Corvus Pharmaceuticals, Curis, CytomX, Daiichi Sankyo, Dracen Pharmaceuticals, Dynavax, Lilly, Elicio Therapeutics, EMD Serono, EQRx, Erasca, Exelixis, Fate Therapeutics, Genentech/Roche, Genmab, Genocea Biosciences, GlaxoSmithKline, Gritstone Oncology, Guardant Health, Harpoon, Helsinn Healthcare SA, Hengrui Therapeutics, Hutchison MediPharma, IDEAYA Biosciences, IGM Biosciences, Immunitas Therapeutics, Immunocore, Incyte, Janssen, Kadmon Pharmaceuticals, Kartos Therapeutics, Loxo Oncology, Lycera, Memorial Sloan-Kettering, Merck, Merus, Mirati Therapeutics, NeoImmune Tech, Neovia Oncology, Novartis, Numab Therapeutics, Nuvalent, OncoMed Pharmaceuticals, Palleon Pharmaceuticals, Pfizer,PMV Pharmaceuticals, Rain Therapeutics, Regeneron Pharmaceuticals, Relay Therapeutics, Revolution Medicines, Ribon Therapeutics, Rubius Therapeutics, Sanofi, Seven and Eight Biopharmaceuticals / Birdie Biopharmaceuticals, Shattuck Labs, Silicon Therapeutics, Stem CentRx, Syndax Pharmaceuticals, Takeda Pharmaceuticals, Tarveda, TCR2 Therapeutics, Tempest Therapeutics, Tizona Therapeutics, TMUNITY Therapeutics, Turning Point Therapeutics, Vyriad, Y-mAbs Therapeutics Consultant: AbbVie, Amgen, Arcus Biosciences, Arrivent, Astellas, AstraZeneca, Axelia Oncology, Black Diamond, Calithera Biosciences, Checkpoint Therapeutics, CytomX Therapeutics, Daiichi Sankyo, EcoR1, Editas Medicine, Eisai, Genentech / Roche, Genmab, Genocea Biosciences, GlaxoSmithKline, Gritstone Oncology, Ideaya Biosciences, Immunocore, iTeos, Janssen, Jazz Pharmaceuticals, Lilly, Merck, Mirati Therapeutics, Molecular Axiom, Novartis, Oncorus, Pyramid Biosciences, Regeneron Pharmaceuticals, Revolution Medicines, Ribon Therapeutics, Sanofi-Aventis, SeaGen, Takeda Pharmaceuticals, Turning Point Therapeutics, VBL Therapeutics

Ticiana Leal, MD
Grant/Research Support: Pfizer, Advaxis Advisory Board: Boehringer Ingelheim, Bayer, Janssen, Mirati, Merck, AstraZeneca, Daiichi-Sankyo, Takeda, Eisai, Amgen, Roche Consultant: Boehringer Ingelheim, Genentech, Lilly, Janssen, Eisai, Novocure, AstraZeneca, Regeneron

Benjamin Levy, MD
Consultant: AstraZeneca, Pfizer, Takeda, Daiichi, Mirati Therapeutics, Janssen, Novartis, Sanofi, Regeneron, Guardant 360, Merck

Jessica Lin, MD
Grant/Research Support: Hengrui Therapeutics, Turning Point Therapeutics, Neon Therapeutics, Relay Therapeutics, Bayer, Elevation Oncology, Roche, Linnaeus Therapeutics, Nuvalent, and Novartis Consultant: Genentech, C4 Therapeutics, Blueprint Medicines, Nuvalent, Bayer, Elevation Oncology, Novartis, Mirati Therapeutics, Regeneron, Pfizer, and Turning Point Therapeutics

Stephen Liu, MD
Grant/Research Support: Alkermes, Bayer, Blueprint, Bristol Myers Squibb, Elevation Oncology, Genentech, Gilead, Merck, Merus, Nuvalent, Pfizer, RAPT, Turning Point Therapeutics Consultant: Amgen, AstraZeneca, Bayer, BeiGene, Blueprint, Bristol Myers Squibb, Catalyst, Daiichi Sankyo, Eisai, Elevation Oncology, Genentech/Roche, Gilead, Guardant Health, Janssen, Jazz Pharmaceuticals, Lilly, MSD, Novartis, Regeneron, Sanofi, Takeda, Turning Point Therapeutics Data Safety Monitoring Board: Candel Therapeutics

Christine Lovly, MD, PhD
Consultant: Amgen, ArriVent, AstraZeneca, Blueprints Medicine, Cepheid, D2G Oncology Inc., Daiichi Sankyo, Eli Lilly, EMD Serono, Foundation Medicine, Genentech, Illumina, Janssen, Novartis, Pfizer, Puma, Roche, Syros, Takeda

Melina Marmarelis, MD, MSCE
Grant/Research Support: Eli Lilly, Trizell, Merck, AstraZeneca Consultant: Boehringer Ingelheim, Novocure, Astra Zeneca, Janssen, Takeda, Blueprint Pharmaceuticals, Bristol Myers Squibb, Ikena, Thermo Fisher Stock Shareholders: Gilead, Merck, Portola Pharmaceuticals, Bluebird Biosciences, Novartis, Johnson & Johnson, Pfizer

Eric Nadler, MP, MPP
Grant/Research Support: Merck, Pfizer Consultant: Merck Speakers' Bureau: Merck, Lilly, AstraZeneca, Genentech, G1, Blueprint, Jazz Pharmaceuticals

Paul Paik, MD
Grant/Research Support: Bicara, EMD Serono Consultant: Novartis, EMD Serono, Xencor, CrownBio, Mirati Therapeutics, Takeda

Keunchil Park, MD, PhD
Grant/Research Support: AstraZeneca, MSD Consultant: AbbVie, Amgen, AstraZeneca, Blueprint, BMS, Boehringer Ingelheim, Daiichi Sankyo, Eisai, Eli Lilly, GENIUS, Gritstone, Hanmi, IMBDx, Janssen Research & Development, LOXO, Merck KGaA, MSD, Ono Pharmaceutical, Puma Biotechnology, Roche, Takeda Speakers' Bureau: AstraZeneca, Boehringer Ingelheim Stock Shareholders: IMBDx, ABION

Sandip Patel, MD
Grant/Research Support: Amgen, AstraZeneca/MedImmune, Bristol Myers Squibb, Eli Lilly, Fate Therapeutics, Gilead, Iovance, Merck, Pfizer, Roche/Genentech, SQZ Biotechnologies Consultant: Amgen, AstraZeneca, Bristol Myers Squibb, Certis, Eli Lilly, Jazz Pharmaceuticals, Genentech, Illumina, Merck, Pfizer, Rakuten, Tempus

Debra Patt, MD, PhD, MBA
Consultant: Pfizer

R. Steven Paulson, MD
Has no relevant financial relationships

Jason Porter, MD
Speakers' Bureau: AstraZeneca Pharmaceuticals, LP, Jazz Pharmaceuticals PLC, Bristol Myers Squibb, Amgen Inc., EMD Serono, G1 Therapeutics, Genentech, Inc., Guardant Health, Inc., Janssen Pharmaceuticals, Mirati Therapeutics, OncoCyte, Pfizer Inc., Regeneron Pharmaceuticals, Takeda USA Inc.

Luis Raez, MD
Grant/Research Support: BMS, Genentech, Amgen, AstraZeneca, Merck, Velos, Guardant Health, Turning Point, Nanth Health, Syndax, Natera, BioAtla

Joshua Reuss, MD
Grant/Research Support : Genentech/Roche, Verastem, Nuvalent Consultant: Genentech/Roche, Sanofi, Genzyme, Personalis, Guardant Health, AstraZeneca, Foundation Medicine, Star Health Institute Speakers’ Bureau: AstraZeneca, Merck

Jonathan Riess, MD, MS
Grant/Research Support: AstraZeneca, Boehringer Ingelheim, Merck, Novartis, Revolution Medicines, Spectrum Pharmaceuticals Consultant: Blueprint, Boehringer Ingelheim, EMD Serono, Novartis Advisory Board: Bayer, BeiGene, Biodesix, Regeneron, Turning Point, Bristol Myers Squibb, Daiichi Sankyo, Roche/Genentech, Janssen, Jazz Pharmaceuticals, Sanofi

Estelamari Rodriguez, MD, MPH
Consultant: Pfizer, Regeneron, Novartis, Janssen, Novocure, Eli Lilly

Julia Rotow, MD
Grant/Research Support: AstraZeneca, AbbVie, BioAtla, Blueprint, Loxo Consultant: AstraZeneca, AbbVie, Gritstone, Lilly, Takeda, Sanofi-Genzyme, Janssen, Genentech, Guardant Health Speakers’ Bureau: AstraZeneca

Edgardo Santos, MD, FACP
Consultant: Amgen, Boehringer Ingelheim, AstraZeneca, Catalyst Pharmaceuticals, Lilly US Oncology, Regeneron, Genentech, Janssen & Janssen, AbbVie, Novocure Speakers' Bureau: Amgen, Boehringer-Ingelheim, AstraZeneca, Lilly US Oncology, Regeneron, Sanofi, Genentech, Jazz Pharmaceutical, Merck, EMD Serono, Astellas, Takeda, G1 Therapeutics

Ferdinandos Skoulidis, MD, PhD
Grant/Research Support: Revolution Medicines, Amgen, Novartis, Merck& Co, Pfizer, Mirati Therapeutics Consultant: AstraZeneca, BeiGene, Novartis, Amgen Inc, Guardant Health, BerGenBio, Navire Pharma, Tango Therapeutics, Calithera Biosciences, Intellisphere LLC, Medscape LLC, Dava Oncology Speakers’ Bureau: Dava Oncology, Guardant Health, Amgen Inc

David Spigel, MD
Grant/Research Support: Aeglea BioTherapeutics, Agios, Apollomics, Arcus, Arrys Therapeutics, Astellas, AstraZeneca, Bayer, BeiGene, IND Therapeutics, BioNTech RNA Pharmaceuticals, Blueprint Medicine, Boehringer Ingelheim, Bristol Myers Squibb, Calithera, Celgene, Celldex, Clovis, Cyteir Therapeutics, Daiichi Sankyo, Denovo Biopharma, Eisai, Elevation Oncology, EMD Serono, Evelo Biosciences, G1 Therapeutics, Roche/Genentech, GlaxoSmithKline, GRAIL, Hutchison MediPharma, ImClone Systems, Incyte, ImmunoGen, Ipsen, Janssen, Kronos Bio, Lilly, Loxo Oncology, MacroGenics, MedImmune, Merck, Molecular Partners, Molecular Template, Nektar, Neon Therapeutics, Novartis, Novocure, Oncologie, Pfizer, PTC Therapeutics, PureTech Health, Razor Genomics, Repare Therapeutics, Rgenix, Takeda, Tesaro, Tizona Therapeutics, Transgene, Verastem Consultant: Amgen, AstraZeneca, Bristol-Myers Squibb, Curio Science , EMD Serono, Evidera, Exelixis, GlaxoSmithKline, Intellisphere, Ipsen Biopharmaceuticals, Janssen, Jazz Pharmaceuticals, Lilly, Mirati Therapeutics, Molecular Templates, Novartis, Novocure, Pfizer, Puma Biotechnology, Regeneron Pharmaceuticals, Roche/Genentech, Sanofi-Aventis

Brendon Stiles, MD
Grant/Research Support: Bristol Myers Squibb, Bristol Myers Squibb Foundation Consultant: AstraZeneca, Pfizer, Bristol Myers Squibb, Arcus Biosciences, Medtronic, Roche-Genentech, Galvanize Therapeutics

Howard “Jack” West, MD
Has no relevant financial relationships

Randi Williams, PhD, MPH
Has no relevant financial relationships

Planning Committee - Reported Relevant Financial Disclosure(s)

Tina Cascone, MD, PhD
Grant/Research Support: MedImmune/AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, EMD Serono Consultant: MedImmune/AstraZeneca, Bristol Myers Squibb, Merck & Co., Genentech, Arrowhead Pharmaceuticals, Regeneron Speakers’ Bureau: Roche, Bristol Myers Squibb, Dava Oncology

Amy Gelhorn, PharmD, MBA
Has no relevant financial relationship

Stephen Liu, MD
Grant/Research Support: Alkermes, Bayer, Blueprint, Bristol Myers Squibb, Elevation Oncology, Genentech, Gilead, Merck, Merus, Nuvalent, Pfizer, RAPT, Turning Point Therapeutics Consultant: Amgen, AstraZeneca, Bayer, BeiGene, Blueprint, Bristol Myers Squibb, Catalyst, Daiichi Sankyo, Eisai, Elevation Oncology, Genentech/Roche, Gilead, Guardant Health, Janssen, Jazz Pharmaceuticals, Lilly, MSD, Novartis, Regeneron, Sanofi, Takeda, Turning Point Therapeutics Data Safety Monitoring Board: Candel Therapeutics Shuba Srinivasan, PA-C Has no relevant financial relationships

Jillian Thompson, MSN- ANP-C
Advisory Board: Janssen


CME Reviewers - Reported Relevant Financial Disclosure(s)

Tina Cascone, MD, PhD
Grant/Research Support: MedImmune/AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, EMD Serono Consultant: MedImmune/AstraZeneca, Bristol Myers Squibb, Merck & Co., Genentech, Arrowhead Pharmaceuticals, Regeneron Speakers’ Bureau: Roche, Bristol Myers Squibb, Dava Oncology

Lynne Davidson
Has no relevant financial relationships

Amy Gelhorn, PharmD, MBA
Has no relevant financial relationships

Stephen Liu, MD
Grant/Research Support: Alkermes, Bayer, Blueprint, Bristol Myers Squibb, Elevation Oncology, Genentech, Gilead, Merck, Merus, Nuvalent, Pfizer, RAPT, Turning Point Therapeutics Consultant: Amgen, AstraZeneca, Bayer, BeiGene, Blueprint, Bristol Myers Squibb, Catalyst, Daiichi Sankyo, Eisai, Elevation Oncology, Genentech/Roche, Gilead, Guardant Health, Janssen, Jazz Pharmaceuticals, Lilly, MSD, Novartis, Regeneron, Sanofi, Takeda, Turning Point Therapeutics Data Safety Monitoring Board: Candel Therapeutics

Shuba Srinivasan, PA-C
Has no relevant financial relationships

Jillian Thompson, MSN- ANP-C
Advisory Board: Janssen

Teri Valls, CMP, CMM
Has no relevant financial relationships

All of the relevant financial relationships listed for these individuals have been mitigated.

SPEAKERS WILL DIRECTLY DISCLOSE THE USE OF PRODUCTS FOR WHICH ARE NOT LABELED (E.G., OFF LABEL USE) OR IF THE PRODUCT IS STILL INVESTIGATIONAL. EACH SPEAKER HAS BEEN REQUESTED TO KEEP THEIR PRESENTATION UNBIASED AND GENERIC WHEN APPLICABLE.